<DOC>
	<DOCNO>NCT00003055</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient locally advance metastatic esophageal gastric cancer .</brief_summary>
	<brief_title>Cisplatin Irinotecan Treating Patients With Locally Advanced Metastatic Esophageal Gastric Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate combine cisplatin irinotecan patient metastatic locally advanced ( inoperable recurrent ) esophageal gastric cancer . II . Evaluate toxic effect qualitatively quantitatively cisplatin irinotecan patient . III . Estimate disease free overall survival patient . IV . Assess whether response proportion differs squamous cell adenocarcinoma esophagus . V. Evaluate quality life issue use Memorial Symptom Assessment Scale , FACT-G questionnaire , dysphagia scale . OUTLINE : Patients receive cisplatin irinotecan day 1 , 8 , 15 , 22 4 week , follow 2 week rest period . Each treatment course last 6 week . Patients receive least 3 course therapy treatment well tolerated disease progression document . Patients attain complete response receive additional course therapy discretion investigator . Tumor status reassess 6 week every 12 week thereafter . Patients follow death . PROJECTED ACCRUAL : A total 28-50 patient accrue within 12-18 month . Accrual adenocarcinoma esophagus complete .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally advanced ( surgically unresectable ) metastatic squamous cell esophagus carcinoma stomach Patients tumor extension GE junction proximal stomach must bulk tumor involve esophagus GE junction Bidimensionally measurable evaluable disease No CNS metastases carcinomatous meningitis No bone metastasis ( Closed adenocarcinoma esophagus 05/1998 ) PATIENT CHARACTERISTICS : Age : 18 Performance Status : Karnofsky 60100 % Life Expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 3 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No unstable angina No New York Heart Association class III IV cardiac disease Pulmonary : No interstitial pulmonary fibrosis Other : Not pregnant nursing Negative pregnancy test No active uncontrolled infection No prior malignancy least 5 year , except : Nonmelanoma skin cancer Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No prior radiation pelvis Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
</DOC>